UNCY vs. ITOS, YMAB, AQST, IMMP, OLMA, ATYR, RZLT, NGNE, CMPX, and AVIR
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include iTeos Therapeutics (ITOS), Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), Rezolute (RZLT), Neurogene (NGNE), Compass Therapeutics (CMPX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Unicycive Therapeutics vs.
iTeos Therapeutics (NASDAQ:ITOS) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
Unicycive Therapeutics' return on equity of 0.00% beat iTeos Therapeutics' return on equity.
In the previous week, iTeos Therapeutics had 4 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 5 mentions for iTeos Therapeutics and 1 mentions for Unicycive Therapeutics. iTeos Therapeutics' average media sentiment score of 0.67 beat Unicycive Therapeutics' score of 0.48 indicating that iTeos Therapeutics is being referred to more favorably in the media.
Unicycive Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics currently has a consensus price target of $22.25, indicating a potential upside of 178.13%. Unicycive Therapeutics has a consensus price target of $5.50, indicating a potential upside of 787.10%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than iTeos Therapeutics.
iTeos Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.
iTeos Therapeutics received 11 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 79.25% of users gave iTeos Therapeutics an outperform vote while only 75.61% of users gave Unicycive Therapeutics an outperform vote.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Unicycive Therapeutics beats iTeos Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UNCY) was last updated on 1/20/2025 by MarketBeat.com Staff
Free UNCY Stock Alerts